[Changes in pharmacotherapy of hospitalized patients with heart failure for 16 years].
Savina
N M
NM
Aleksandrova
A Iu
AIu
Sidorenko
B A
BA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002301:Cardiac Glycosides / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004358:Drug Therapy / Q000639:trends; D006333:Heart Failure / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009031:Moscow / Q000453:epidemiology; D018377:Neurotransmitter Agents / Q000627:therapeutic use; D010043:Outcome and Process Assessment, Health Care
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002301:Cardiac Glycosides; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D018377:Neurotransmitter Agents